• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年轻膀胱癌患者的临床结局和预后分析。

Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients.

机构信息

Department of Urology, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, China.

Department of Urology, Naval Military Medical University Affiliated Gongli Hospital, Shanghai 200135, China.

出版信息

Curr Oncol. 2022 Jan 28;29(2):578-588. doi: 10.3390/curroncol29020052.

DOI:10.3390/curroncol29020052
PMID:35200552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8870851/
Abstract

BACKGROUND

Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients.

METHODS

We collected clinicopathological data on bladder cancer patients ≤40 years old diagnosed between 1975 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database. Survival curves were generated using the Kaplan-Meier method, and the differences between groups were analyzed using the log-rank test. Univariate and multivariate Cox hazards regression analyses were performed to define hazard ratios (HRs) for cancer-specific survival (CSS).

RESULTS

There were statistical differences in race, histological type, cancer stage, tumor size, and surgery treatment groups between overall survival and CSS. Only tumor size and cancer stage were significant independent prognostic risk factors in younger bladder cancer patients for the prediction of CSS.

CONCLUSION

Tumors greater than 30 mm in size and a more advanced stage of bladder cancer were indicative of a poor prognosis in bladder cancer patients ≤40 years old, and long-term follow-up is suggested.

摘要

背景

一般来说,人们对 40 岁以下膀胱癌患者的预后因素知之甚少。因此,我们进行了一项回顾性研究,以确定这些年轻膀胱癌患者的预后因素。

方法

我们从监测、流行病学和最终结果 (SEER) 数据库中收集了 1975 年至 2018 年间诊断的≤40 岁膀胱癌患者的临床病理数据。使用 Kaplan-Meier 方法生成生存曲线,并使用对数秩检验分析组间差异。进行单因素和多因素 Cox 风险回归分析,以定义癌症特异性生存 (CSS) 的风险比 (HR)。

结果

总生存和 CSS 之间在种族、组织学类型、癌症分期、肿瘤大小和手术治疗组方面存在统计学差异。只有肿瘤大小和癌症分期是年轻膀胱癌患者 CSS 预测的显著独立预后危险因素。

结论

肿瘤大于 30mm 且膀胱癌分期较高的患者预后较差,建议进行长期随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/7f4f96fc49d5/curroncol-29-00052-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/0c70a2b76709/curroncol-29-00052-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/94c449adc6e1/curroncol-29-00052-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/128f2560fa99/curroncol-29-00052-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/55e88a17b335/curroncol-29-00052-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/7f4f96fc49d5/curroncol-29-00052-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/0c70a2b76709/curroncol-29-00052-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/94c449adc6e1/curroncol-29-00052-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/128f2560fa99/curroncol-29-00052-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/55e88a17b335/curroncol-29-00052-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8870851/7f4f96fc49d5/curroncol-29-00052-g005.jpg

相似文献

1
Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients.年轻膀胱癌患者的临床结局和预后分析。
Curr Oncol. 2022 Jan 28;29(2):578-588. doi: 10.3390/curroncol29020052.
2
Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: A SEER database analysis with 19,919 patients.膀胱癌膀胱颈部侵犯的预后意义:基于 19919 例患者的 SEER 数据库分析。
Cancer Med. 2021 Oct;10(19):6868-6880. doi: 10.1002/cam4.4219. Epub 2021 Aug 23.
3
A Clinical Model of Bone Angiosarcoma Patients: A Population-based Analysis of Epidemiology, Prognosis, and Treatment.骨血管肉瘤患者的临床模型:基于人群的流行病学、预后和治疗分析。
Orthop Surg. 2020 Dec;12(6):1652-1662. doi: 10.1111/os.12803. Epub 2020 Sep 10.
4
Smaller tumor size is associated with poor survival in stage II colon cancer: An analysis of 7,719 patients in the SEER database.肿瘤体积越小,Ⅱ期结肠癌患者的生存预后越差:SEER 数据库中 7719 例患者的分析。
Int J Surg. 2016 Sep;33 Pt A:157-63. doi: 10.1016/j.ijsu.2016.07.073. Epub 2016 Aug 2.
5
Development and validation of a prognostic nomogram for predicting overall survival in patients with primary bladder sarcoma: a SEER-based retrospective study.基于 SEER 的回顾性研究:开发和验证用于预测原发性膀胱肉瘤患者总生存期的预后列线图。
BMC Urol. 2021 Nov 25;21(1):162. doi: 10.1186/s12894-021-00929-x.
6
The incidence and survival outcomes of patients with primary cardiac lymphoma: A SEER-based analysis.原发性心脏淋巴瘤患者的发病和生存结局:基于 SEER 的分析。
Hematol Oncol. 2020 Aug;38(3):334-343. doi: 10.1002/hon.2741. Epub 2020 Apr 29.
7
Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study.回顾原发性膀胱腺癌的人口统计学、预后和治疗因素:一项 SEER 基于人群的研究。
Clin Genitourin Cancer. 2019 Oct;17(5):380-388. doi: 10.1016/j.clgc.2019.06.010. Epub 2019 Jun 26.
8
Survival Analysis of Patients with Osseous Malignant Vascular Tumors: Results of the Surveillance, Epidemiology, and End Results (SEER) Database from 1973 to 2015.骨质恶性血管肿瘤患者的生存分析:1973 年至 2015 年监测、流行病学和最终结果(SEER)数据库的结果。
Med Sci Monit. 2019 Jul 25;25:5525-5535. doi: 10.12659/MSM.914950.
9
The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis.远处转移性膀胱癌患者转移模式对总生存期的预后影响:一项基于 SEER 人群的分析。
World J Urol. 2021 Nov;39(11):4151-4158. doi: 10.1007/s00345-021-03721-6. Epub 2021 May 24.
10
Impact of Age on the Prognosis of Operable Gastric Cancer Patients: An Analysis Based on SEER Database.年龄对可手术胃癌患者预后的影响:基于监测、流行病学和最终结果(SEER)数据库的分析
Medicine (Baltimore). 2016 Jun;95(24):e3944. doi: 10.1097/MD.0000000000003944.

引用本文的文献

1
Changing Clinical Spectrum and Disease Progression in Young Patients With Bladder Cancer: A Retrospective Observational Study.年轻膀胱癌患者临床谱及疾病进展的变化:一项回顾性观察研究
Cureus. 2025 Apr 18;17(4):e82516. doi: 10.7759/cureus.82516. eCollection 2025 Apr.
2
The Role of AHCY Expression in Bladder Urothelial Carcinoma: A Bioinformatics and Experimental Analysis.AHCY表达在膀胱尿路上皮癌中的作用:一项生物信息学与实验分析
Cancer Manag Res. 2025 Mar 21;17:661-673. doi: 10.2147/CMAR.S491044. eCollection 2025.
3
The Added-value of Staging F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.

本文引用的文献

1
Young age increases the risk of lymph node positivity but improves prognosis in patients with bladder cancer treated via cystectomy: a population-based study.一项基于人群的研究表明:年轻会增加膀胱癌患者淋巴结阳性的风险,但接受膀胱切除术治疗的年轻膀胱癌患者预后更佳。
Transl Androl Urol. 2021 Aug;10(8):3375-3385. doi: 10.21037/tau-21-99.
2
Incidence trends and survival prediction of urothelial cancer of the bladder: a population-based study.膀胱尿路上皮癌的发病率趋势及生存预测:一项基于人群的研究。
World J Surg Oncol. 2021 Jul 26;19(1):221. doi: 10.1186/s12957-021-02327-x.
3
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
分期F-FDG PET/CT在预测膀胱癌患者总生存中的附加值
Mol Imaging Radionucl Ther. 2024 Feb 22;33(1):11-18. doi: 10.4274/mirt.galenos.2023.65002.
4
Competitive Risk Model for Specific Mortality Prediction in Patients with Bladder Cancer: A Population-Based Cohort Study with Machine Learning.膀胱癌患者特定死亡率预测的竞争风险模型:一项基于人群队列的机器学习研究
J Oncol. 2022 Aug 25;2022:9577904. doi: 10.1155/2022/9577904. eCollection 2022.
帕博利珠单抗单药治疗卡介苗(BCG)无应答的高风险非肌肉浸润性膀胱癌(KEYNOTE-057):一项开放标签、单臂、多中心、2 期研究。
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.
4
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.根治性膀胱切除术联合膀胱内卡介苗治疗高危高级别非肌肉浸润性膀胱癌:随机对照 BRAVO-可行性研究结果。
J Clin Oncol. 2021 Jan 20;39(3):202-214. doi: 10.1200/JCO.20.01665. Epub 2020 Dec 17.
5
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2020 年更新版。
Eur Urol. 2021 Jan;79(1):62-79. doi: 10.1016/j.eururo.2020.05.042. Epub 2020 Jun 24.
6
Nomogram for predicting overall survival of patients with bladder cancer: A population-based study.膀胱癌患者总生存预测列线图:一项基于人群的研究。
Int J Biol Markers. 2020 Jun;35(2):29-39. doi: 10.1177/1724600820907605. Epub 2020 Apr 20.
7
Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer.新辅助化疗与辅助化疗在肌层浸润性膀胱癌中的比较。
Clin Genitourin Cancer. 2020 Jun;18(3):201-209.e2. doi: 10.1016/j.clgc.2019.12.011. Epub 2019 Dec 14.
8
Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer.未婚男性在根治性膀胱切除术治疗非转移性尿路上皮膀胱癌后的肿瘤学结局更差。
Urol Oncol. 2020 Mar;38(3):76.e1-76.e9. doi: 10.1016/j.urolonc.2019.10.018. Epub 2019 Nov 21.
9
Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer.一种用于预测肌层浸润性膀胱癌总生存期的新型12基因标志物的开发与外部验证
Front Oncol. 2019 Sep 6;9:856. doi: 10.3389/fonc.2019.00856. eCollection 2019.
10
Validation of the Eighth AJCC New Substages for Bladder Cancer Among Different Staging Contexts.第八版 AJCC 膀胱癌新亚分期在不同分期环境下的验证。
Clin Genitourin Cancer. 2017 Dec;15(6):e1095-e1106. doi: 10.1016/j.clgc.2017.07.025. Epub 2017 Aug 3.